About XCELTHERA
Founded to leverage stem cell therapy and regenerative medicine development and manufacturing innovations to provide the next generation of cell-based therapeutic solutions for unmet medical needs. A major innovator in the stem cell research and regenerative medicine market, and the first to hold IP for large-scale production of high quality clinical-grade human embryonic stem cell lines (hESC) and their functional human neuronal and heart cell therapy products. Its PluriXcel technology provides clinical-grade translating capabilities to address key challenges to traditional medicine & biofabrication, and its Xcel therapy products offer currently the only available human cell sources in large quantity and high quality with adequate capacity to regenerate contractile heart muscle and neuron circuitry, overcoming major bottlenecks for tissue repair & biofabrication, and vital for regenerative medicine advanced therapies for a wide range of neurological and cardiovascular diseases.
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to XCELTHERA right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.